AutismNCT07533331
Testing Conversational Agents as a Digital Companion
A study testing self-directed goal coaching in people with Autism, run by Friendi.fi Corporation at 3 sites in United States.
Trial summary
There is a need and opportunity to improve the supports, transitions, and life outcomes of people with autism spectrum disorder. Compared to their neurotypical peers, autistic teenagers and adults report poorer mental health and quality of life and have higher rates of unemployment or underemployment and low… Read more about this study
- Who is it for?
- Ages 18 to 35 years
- Conditions the study is for
- Autism
- What is being tested?
- self-directed goal coaching
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- 3 sitesUnited States
- Study dates
- 21 Mar 2026to Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- formal autism diagnosis per qualified professional.
- holds a job, volunteers, or attends college/vocational school where they participate in regular course work, classrooms, settings.
- drives or independently uses public transportation/ride share.
- makes medical decisions and manages finances.
- purchases groceries and cooks meals.
- engages in leisure activities with peers.
Show all 10Show fewer
- reads and comprehends spoken and written English.
- able to complete surveys and informed consent independently.
- able and willing to identify a trusted informant (such as a good friend, parent proxy or mentor who knows them well) for additional context, if needed.
- 24/7 access to a personal mobile phone with SMS text capability.
Who cannot join
- an intellectual disability.
- serious mental illness requiring psychiatric evaluation, intervention or in-patient hospitalizations in the past month.
- suicidal ideation or attempts in the past month.
- diagnosed sleep disorder in the past month.
- pregnancy.
- planned absences that interfere with study participation.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States3 sites, 3 recruiting
- Recruiting
Indiana Institute on Disability and Community
Bloomington, Indiana, 47408
Judith Gross, PhD, 812-855-7484, jmsgross@iu.edu
Judith Gross, PhD
- Recruiting
Norton Children's Autism Center502-588-0736 x 50608
Louisville, Kentucky, 40202
Grace Kuravackel, PhD, 502-588-0736 ext. 50608, grace.kuravackel@louisville.edu
Grace Kuravackel, PhD
- Recruiting
Ball State University
Muncie, Indiana, 47306
Evette Simmons-Reed, PhD, 765-285-2762, easimmonsree@bsu.edu
Evette Simmons-Reed, PhD
About this study
Official title: Pilot Test the Digital Intervention and Research Protocols in a Small Clinical Trial
There is a need and opportunity to improve the supports, transitions, and life outcomes of people with autism spectrum disorder. Compared to their neurotypical peers, autistic teenagers and adults report poorer mental health and quality of life and have higher rates of unemployment or underemployment and low participation in post-secondary education. Nearly 40% spend little or no time with friends. Although autism awareness has grown considerably in recent decades, much more can be done to improve the life outcomes for people with autism. Cost-effective, affordable and scalable support systems are needed as well as ongoing assessments and personalized support plans that focus on individual strengths and challenges in different contexts (college, work, community life) across the life span. This requires adaptive interventions and regular consultation with and between stakeholders. It also requires a rigorous approach to measuring outcomes that are not one-size-fits-all and do not expect everyone to reach, or have, the same goals. To meet these needs, the investigators leverage an already successful technology platform with two conversational-relational agents to be a digital companion and coach to autistic young adults (AYA, ages 18 to 35 years). The technology will be used to scale a strong theoretical and conceptual approach that has proven successful in meeting the individual needs and personalized outcomes of autistic students through a collaborative consultation model for promoting competency and success (COMPASS) combined with Goal Attainment Scaling (GAS). To deliver personalized coaching, empathy, and outcomes at scale, GAS/COMPASS was translated into software-driven evidence-based coaching protocols in collaboration with clinical, academic, and community partners. In this study, the digital coaching program and all research protocols are pilot tested in a 10-week experiential trial with AYA.
Read the detailed description
There is a need and opportunity to improve the supports, transitions, and life outcomes of people with autism spectrum disorder (ASD). Autism affects about 5.4 million adults in America (2.2% or 1 in 45 adults) and at least 78 million people and their families worldwide.1,2 Estimates for children are similar (1 in 44). Classified as a neurodevelopmental disorder, autism typically manifests in early childhood before the age of 3 years and affects social and communication skills, behavior, and outcomes throughout the life span. Teenagers and adults with autism have higher rates of unemployment or underemployment, low participation in post-secondary education, and nearly 40% spend little or no time with friends. Although awareness and scientific interest has grown significantly over the past 20 years, many children and adults are not diagnosed until later in life and much more can be done to improve the life outcomes for people with autism. Large knowledge gaps exist, such as what support strategies are effective for whom and when, and which ones have long-term and meaningful impact. Essentially, the mechanisms of positive change in autism, both behavioral and neurobiological, are largely unknown. Because autism has major implications for lifelong outcomes, cost-effective, affordable and scalable support systems are key, yet missing for many individuals and families.
Given that autism is a complex, heterogenous developmental condition that changes with and affects development, The Lancet Commission on the future of care and clinical research in autism recently stated that single assessments and treatments are never sufficient in ASD. Ongoing assessments and personalized supports that focus on individual strengths and challenges in different contexts across the life span are needed. Meanwhile, autistic people, their family members and community organizations have called for greater emphasis on enhancing quality of life (QOL). The World Health Organization (WHO) defines QOL as "an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns". In response, investigators at the Center for Autism Research Center at Children's Hospital of Philadelphia leveraged the patient reported outcome measurement information system (PROMIS) developed by the NIH to comprehensively assess QOL in autism, across age groups and genders. The PROMIS Autism Battery (PAB) includes 18 self-report scales for adults that show profound differences between autistic and neurotypical adult samples across virtually all PAB domains, including subjective wellbeing (SWB), relationships (including supports, companionship and social isolation), emotional distress (including anxiety and depression), health (including sleep and mental health), and adulthood (including self-efficacy).
In response to these needs and to NIMH's special topic of interest to "Develop and test new and augment existing digital health interventions that are personalized, engaging, adaptive, sufficiently challenging, and optimal for maximizing real world functional improvements," Friendi.fi Corporation (Friendi.fi) is leveraging its AI-driven technology platform and conversational agent that works on mobile phones through standard SMS (Short Message Service) texting, to be a mobile digital companion to autistic people in early adulthood. The platform and agent is used to scale a strong theoretical and conceptual approach that has proven successful in meeting the individual needs and targeted outcomes of autistic students through a collaborative model for promoting competence and success (COMPASS) combined with Goal Attainment Scaling (GAS). COMPASS considers the challenges and strengths of the individual and environment, as well as the balance between them. Critically, the role of the environment as an enabler (support) or barrier (challenge) to success lowers the burden on autistic individuals as a source of dysfunction. In this model, technology is viewed as an environmental support that builds on the strengths, needs, and goals of the individual.
AYA will be enrolled in a 10-week experiential trial using the novel digital coaching program and agent. The trial serves several purposes: (1) It will test the preliminary efficacy of the digital intervention by assessing within-person change over time. The trial is powered to detect a minimal important change (MIC) in the proposed standardized and normalized PAB measures; (2) The observed effect size will be used to finalize the sample size calculation for a properly-powered future randomized control trial (RCT); (3) By including a control group, the feasibility of all clinical and study protocols is tested prior to implementing the RCT. Twenty-six AYA will receive daily coaching via the digital agents (AGENT group) and twelve will receive traditional coaching using face-to-face meetings with human counselors (CONTROL group). In both groups, intervention delivery and patient-reported outcomes data are collected.
- Conditions
- Autism
- Being tested
- self-directed goal coaching
- Keywords
- Digital companions, mental health, autistic young adults, self-determination, goal attainment
- Medical subject headings
- Autistic Disorder, Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
self-directed goal coachingBehavioural
a collaborative model for promoting competence and success (COMPASS) combined with Goal Attainment Scaling (GAS).
| Study group | Role | What they receive |
|---|---|---|
| AGENT | Experimental | goal coaching intervention via digital companion Receives: Behavioral: self-directed goal coaching |
| CONTROL | Active comparator | goal coaching using traditional face-to-face meetings with human counselors and paper-and-pencil materials. Receives: Behavioral: self-directed goal coaching |
What is being measured
The primary outcome is the main question the study is designed to answer.
Global Mental Health
PROMIS Scale v1.2-Global Mental 2a: Patient-Reported Outcomes Measurement Information System, 2 items assessing overall mental health, emotional well-being, and quality of life. Minimum possible standardized T-score: approximately 21; Maximum possible score: approximately 68. Raw scores range from 2 to 10. Higher scores indicate a better outcome.
Measured: 10 weeks
Anxiety
PROMIS Short Form v1.0-Anxiety 4a. Patient-Reported Outcomes Measurement Information System, 4 items assessing emotional distress related to fears, worries, nervousness experienced over the past 7 days. Scored using IRT-based T-scores. Minimum possible T-score approximately 40; Maximum possible score approximately 82. Raw scores range from 4 to 20. Higher scores indicate a worse outcome.
Measured: 10 weeks
Secondary outcomes (2)
Goal Attainment
Goal Attainment Scale (GAS) which assesses the extent to which individualized goals are achieved over a specified period of time relative to an expected level of goal achievement, not absolute ability or symptom severity. Scores range from 1 (no progress) to 5 (exceeds goal). Higher scores indicate a better outcome.
Measured: 10 weeks
Self Efficacy
PROMIS_SF_v1.0_Self_Effic-General_4a. Patient-Reported Outcomes Measurement Information System, 4 items assessing an individual's confidence in their ability to handle problems, achieve goals, and manage difficult or unexpected situations. Scored using standardized T-scores. Minimum possible T-score approximately 28; Maximum possible score approximately 69. Raw scores range from 4 to 20. Higher scores indicate a better outcome.
Measured: 10 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Apr 2026
- Study start21 Mar 2026
- Primary completionSep 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AutismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a pilot clinical trial, where participants are randomly assigned to one of two groups. All participants will receive a health coaching program. What differs between the groups is how the program is delivered. Participants in the CONTROL group will be coached using traditional methods (face-to-face meetings and paper-and-pencil materials). The digital intervention group will complete all coaching components, including intake, coaching, progress monitoring and evaluation, using a digital companion (AGENT group). At the end of the program, all participants complete the same assessments to see if they benefited from the intervention, and if the delivery mode made a difference.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 38 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Friendi.fi Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- National Institute of Mental Health (NIMH), University of Louisville, Indiana University, Ball State University, University of Nebraska
- Responsible party
- Sponsor
- Investigators
- Chantal Kerssens, PhD, Principal investigator, Friendi.fi Corporation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07533331
- Sponsor's protocol ID
- 14023
- Other IDs
- 5R44MH134719-03
- Status last verified
- Apr 2026
- First submitted
- 3 Apr 2026
- Last updated
- 16 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Test the Digital Intervention and Research Protocols in a Small Clinical Trial
- ClinicalTrials.gov ID
- NCT07533331
- Acronym / sponsor ID
- 14023
- Conditions
- Autism
- Keywords
- Digital companions, mental health, autistic young adults, self-determination, goal attainment
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 38 participants (estimated)
- Lead sponsor
- Friendi.fi CorporationIndustry (pharma, biotech, devices)
- Collaborators
- National Institute of Mental Health (NIMH), University of Louisville, Indiana University, Ball State University, University of Nebraska
- Study start
- 21 Mar 2026 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 16 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There is a need and opportunity to improve the supports, transitions, and life outcomes of people with autism spectrum disorder. Compared to their neurotypical peers, autistic teenagers and adults report poorer mental health and quality of life and have higher rates of unemployment or underemployment and low participation in post-secondary education. Nearly 40% spend little or no time with friends. Although autism awareness has grown considerably in recent decades, much more can be done to improve the life outcomes for people with autism. Cost-effective, affordable and scalable support systems are needed as well as ongoing assessments and personalized support plans that focus on individual strengths and challenges in different contexts (college, work, community life) across the life span. This requires adaptive interventions and regular consultation with and between stakeholders. It also requires a rigorous approach to measuring outcomes that are not one-size-fits-all and do not expect everyone to reach, or have, the same goals. To meet these needs, the investigators leverage an already successful technology platform with two conversational-relational agents to be a digital companion and coach to autistic young adults (AYA, ages 18 to 35 years). The technology will be used to scale a strong theoretical and conceptual approach that has proven successful in meeting the individual needs and personalized outcomes of autistic students through a collaborative consultation model for promoting competency and success (COMPASS) combined with Goal Attainment Scaling (GAS). To deliver personalized coaching, empathy, and outcomes at scale, GAS/COMPASS was translated into software-driven evidence-based coaching protocols in collaboration with clinical, academic, and community partners. In this study, the digital coaching program and all research protocols are pilot tested in a 10-week experiential trial with AYA.
Detailed description
There is a need and opportunity to improve the supports, transitions, and life outcomes of people with autism spectrum disorder (ASD). Autism affects about 5.4 million adults in America (2.2% or 1 in 45 adults) and at least 78 million people and their families worldwide.1,2 Estimates for children are similar (1 in 44). Classified as a neurodevelopmental disorder, autism typically manifests in early childhood before the age of 3 years and affects social and communication skills, behavior, and outcomes throughout the life span. Teenagers and adults with autism have higher rates of unemployment or underemployment, low participation in post-secondary education, and nearly 40% spend little or no time with friends. Although awareness and scientific interest has grown significantly over the past 20 years, many children and adults are not diagnosed until later in life and much more can be done to improve the life outcomes for people with autism. Large knowledge gaps exist, such as what support strategies are effective for whom and when, and which ones have long-term and meaningful impact. Essentially, the mechanisms of positive change in autism, both behavioral and neurobiological, are largely unknown. Because autism has major implications for lifelong outcomes, cost-effective, affordable and scalable support systems are key, yet missing for many individuals and families.
Given that autism is a complex, heterogenous developmental condition that changes with and affects development, The Lancet Commission on the future of care and clinical research in autism recently stated that single assessments and treatments are never sufficient in ASD. Ongoing assessments and personalized supports that focus on individual strengths and challenges in different contexts across the life span are needed. Meanwhile, autistic people, their family members and community organizations have called for greater emphasis on enhancing quality of life (QOL). The World Health Organization (WHO) defines QOL as "an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns". In response, investigators at the Center for Autism Research Center at Children's Hospital of Philadelphia leveraged the patient reported outcome measurement information system (PROMIS) developed by the NIH to comprehensively assess QOL in autism, across age groups and genders. The PROMIS Autism Battery (PAB) includes 18 self-report scales for adults that show profound differences between autistic and neurotypical adult samples across virtually all PAB domains, including subjective wellbeing (SWB), relationships (including supports, companionship and social isolation), emotional distress (including anxiety and depression), health (including sleep and mental health), and adulthood (including self-efficacy).
In response to these needs and to NIMH's special topic of interest to "Develop and test new and augment existing digital health interventions that are personalized, engaging, adaptive, sufficiently challenging, and optimal for maximizing real world functional improvements," Friendi.fi Corporation (Friendi.fi) is leveraging its AI-driven technology platform and conversational agent that works on mobile phones through standard SMS (Short Message Service) texting, to be a mobile digital companion to autistic people in early adulthood. The platform and agent is used to scale a strong theoretical and conceptual approach that has proven successful in meeting the individual needs and targeted outcomes of autistic students through a collaborative model for promoting competence and success (COMPASS) combined with Goal Attainment Scaling (GAS). COMPASS considers the challenges and strengths of the individual and environment, as well as the balance between them. Critically, the role of the environment as an enabler (support) or barrier (challenge) to success lowers the burden on autistic individuals as a source of dysfunction. In this model, technology is viewed as an environmental support that builds on the strengths, needs, and goals of the individual.
AYA will be enrolled in a 10-week experiential trial using the novel digital coaching program and agent. The trial serves several purposes: (1) It will test the preliminary efficacy of the digital intervention by assessing within-person change over time. The trial is powered to detect a minimal important change (MIC) in the proposed standardized and normalized PAB measures; (2) The observed effect size will be used to finalize the sample size calculation for a properly-powered future randomized control trial (RCT); (3) By including a control group, the feasibility of all clinical and study protocols is tested prior to implementing the RCT. Twenty-six AYA will receive daily coaching via the digital agents (AGENT group) and twelve will receive traditional coaching using face-to-face meetings with human counselors (CONTROL group). In both groups, intervention delivery and patient-reported outcomes data are collected.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- This study is a pilot clinical trial, where participants are randomly assigned to one of two groups. All participants will receive a health coaching program. What differs between the groups is how the program is delivered. Participants in the CONTROL group will be coached using traditional methods (face-to-face meetings and paper-and-pencil materials). The digital intervention group will complete all coaching components, including intake, coaching, progress monitoring and evaluation, using a digital companion (AGENT group). At the end of the program, all participants complete the same assessments to see if they benefited from the intervention, and if the delivery mode made a difference.
| Arm | Type | Receives |
|---|---|---|
| AGENT | Experimental | Behavioral: self-directed goal coachinggoal coaching intervention via digital companion |
| CONTROL | Active comparator | Behavioral: self-directed goal coachinggoal coaching using traditional face-to-face meetings with human counselors and paper-and-pencil materials. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- formal autism diagnosis per qualified professional.
- holds a job, volunteers, or attends college/vocational school where they participate in regular course work, classrooms, settings.
- drives or independently uses public transportation/ride share.
- makes medical decisions and manages finances.
- purchases groceries and cooks meals.
Key exclusion criteria (6 listed)
- an intellectual disability.
- serious mental illness requiring psychiatric evaluation, intervention or in-patient hospitalizations in the past month.
- suicidal ideation or attempts in the past month.
- diagnosed sleep disorder in the past month.
- pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| self-directed goal coachinga collaborative model for promoting competence and success (COMPASS) combined with Goal Attainment Scaling (GAS). | Behavioural | AGENT, CONTROL |
Primary outcome
Global Mental Health
Time frame: 10 weeks
PROMIS Scale v1.2-Global Mental 2a: Patient-Reported Outcomes Measurement Information System, 2 items assessing overall mental health, emotional well-being, and quality of life. Minimum possible standardized T-score: approximately 21; Maximum possible score: approximately 68. Raw scores range from 2 to 10. Higher scores indicate a better outcome.
Anxiety
Time frame: 10 weeks
PROMIS Short Form v1.0-Anxiety 4a. Patient-Reported Outcomes Measurement Information System, 4 items assessing emotional distress related to fears, worries, nervousness experienced over the past 7 days. Scored using IRT-based T-scores. Minimum possible T-score approximately 40; Maximum possible score approximately 82. Raw scores range from 4 to 20. Higher scores indicate a worse outcome.
2 secondary outcomes
Goal Attainment
Time frame: 10 weeks
Self Efficacy
Time frame: 10 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Autism
Not yet recruiting
Single Session Support for Parents of Children With Neurodevelopmental Disabilities Struggling With Anxious Avoidance
Neurodevelopmental Disorders, Autism Spectrum Disorder (ASD)
Not yet recruiting
Evaluation of a Novel Quantum-Inspired Intervention (QII) for Children With Autism Spectrum Disorder: A Global Confirmatory Study
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD
Recruiting
Strategies for Toddler ASD With Remote-therapy (STAR) Model for ASD
Autism Spectrum Disorder, Therapy
Recruiting
Smith Magenis Syndrome and Autism Spectrum Disorders
Smith-Magenis Syndrome, Autism Spectrum Disorder
Active, not recruitingPhase 1
Psilocybin for Treatment-Resistant Depression in Autism
Treatment Resistant Depression, Autism Spectrum Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chantal Kerssens, PhD principal investigator
Friendi.fi Corporation
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing self-directed goal coaching in people with Autism, run by Friendi.fi Corporation at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chantal Kerssens, PhD (404-282-0378, chantal@friendi.fi), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Global Mental Health (time frame: 10 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2026.